Biren Amin
Stock Analyst at Piper Sandler
(3.13)
# 1,108
Out of 5,124 analysts
66
Total ratings
49.15%
Success rate
1.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Overweight | $7 | $2.01 | +248.26% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $26.24 | +82.93% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $21.52 | -25.65% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $76.49 | +28.12% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $16.00 | +318.75% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $12.14 | +155.46% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $65.30 | +45.48% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $3.01 | +99.34% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $1.47 | +172.11% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $5.64 | +201.42% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.37 | +410.95% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $25.01 | +51.94% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.37 | +123.46% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $35.18 | +101.82% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.14 | +329.98% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $21.48 | -2.23% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $65.20 | +76.38% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $25.12 | +27.39% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.14 | -4.46% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.35 | +5,104.46% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.57 | +8,883.62% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.18 | +363.32% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.50 | +518.18% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.56 | +89,844.23% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $10.50 | +33.33% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $771.87 | -10.48% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.26 | +134.74% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $48.48 | +108.33% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $141.83 | -51.35% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $453.36 | -65.81% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $4.02 | +3,283.08% | 4 | Mar 6, 2017 |
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $2.01
Upside: +248.26%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $26.24
Upside: +82.93%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $21.52
Upside: -25.65%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $76.49
Upside: +28.12%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $16.00
Upside: +318.75%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $12.14
Upside: +155.46%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $65.30
Upside: +45.48%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $3.01
Upside: +99.34%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $1.47
Upside: +172.11%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.64
Upside: +201.42%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.37
Upside: +410.95%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $25.01
Upside: +51.94%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.37
Upside: +123.46%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $35.18
Upside: +101.82%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.14
Upside: +329.98%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $21.48
Upside: -2.23%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $65.20
Upside: +76.38%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $25.12
Upside: +27.39%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.14
Upside: -4.46%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.35
Upside: +5,104.46%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.57
Upside: +8,883.62%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.18
Upside: +363.32%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $5.50
Upside: +518.18%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.56
Upside: +89,844.23%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $10.50
Upside: +33.33%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $771.87
Upside: -10.48%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.26
Upside: +134.74%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $48.48
Upside: +108.33%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $141.83
Upside: -51.35%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $453.36
Upside: -65.81%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $4.02
Upside: +3,283.08%